Allena Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. ’s lumasiran already is on track to become the first approved drug therapy for the ultra-rare renal disorder primary hyperoxaluria 1 (PH1), but top-line data the biotech u

Allena Pharmaceuticals Inc. ’s reloxaliase reduced kidney stone formation in two patient populations . But unexpectedly high placebo results from one trial could hamper the small biotech firm in se

Here's your US review and approval news for the week in brief: Three more companies picked up breakthrough therapy designations this week – Alnylam Pharmaceuticals Inc. , Proteostasis Therapeutics I

Sanofi 's decision not to opt-in to the development and commercialization of ultra-orphan therapy lumasiran is considered a positive for the product's originator, Alnylam Pharmaceuticals Inc. , but t